A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
about
The promise of neuroprotective agents in Parkinson's diseaseHippocampal Neurophysiologic Changes after Mild Traumatic Brain Injury and Potential Neuromodulation Treatment ApproachesParkinson's disease, insulin resistance and novel agents of neuroprotectionGut-brain peptides in corticostriatal-limbic circuitry and alcohol use disordersProtein-tyrosine phosphatase (PTP) wedge domain peptides: a novel approach for inhibition of PTP function and augmentation of protein-tyrosine kinase functionExendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosisExenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in RatsA synopsis on the role of tyrosine hydroxylase in Parkinson's diseaseThe entero-insular axis: implications for human metabolism.GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons.Exenatide and the treatment of patients with Parkinson's diseaseExendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cellsEnhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injuryChronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model.Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and rewardSite-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activityGlucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities.Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetesGLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic miceNeuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic ratsEvidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disordersClass II G protein-coupled receptors and their ligands in neuronal function and protectionAmelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4.GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptidesGlucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats.Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection.Incretin-based therapies.Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1.Cardiovascular autonomic neuropathies as complications of diabetes mellitus.Fructus Gardenia (Gardenia jasminoides J. Ellis) phytochemistry, pharmacology of cardiovascular, and safety with the perspective of new drugs development.
P2860
Q21129436-0720E5E3-76E7-44E0-B69C-BE518B403294Q26768199-0C68FEA2-DF17-4B28-9D1B-B1C6F4F7493EQ26853311-EDBF78CD-F508-4AD3-B58D-C0290848EAA6Q27014840-E679D9E3-0294-4775-B2E1-7F4A0D04A235Q28307065-1F3A529D-8CDA-4674-9BC2-9B7810F8B3DBQ28481242-58D28FC3-1F51-46B3-B81B-E580385543EFQ28550675-F17BFB1A-0BD4-413A-8EE8-3C1CE20E2D0CQ28830946-1230A657-7AE2-4054-98E2-18A0B19E0C6AQ30365939-36901DC4-9D7C-4796-8622-08FF9D91ACA4Q30497661-7529060A-1ACC-4BC0-9D71-5825BEC573B4Q30540208-6203087B-D140-4207-BA77-483E6D0302F1Q31131659-0D41FBFC-3648-470D-83EB-243DAB0EDAF8Q34028497-479F5763-2214-4E73-9C9B-65E9090EBCD5Q34167980-EEB1CBD8-F503-491D-97B1-94AEE985B157Q34362412-6ECE5424-BFF6-49FB-8A02-D076749164B5Q34639384-3885CEA4-9925-4841-8485-CFB38F7580D7Q34685472-E970EC1A-C984-4EE8-A822-2C04BA6D9F25Q34919698-2FD616A7-C2DF-4291-858D-ACA07B19E0A9Q35070673-EEC0D1BA-EC7B-44CB-A95E-5B4C2C36D7A8Q35180081-986D4445-40D4-4C78-97D9-A85542E729ACQ35213829-3D58EDA9-FA8B-4588-B565-1CE6EDAA4497Q35226164-4FDCF200-8897-48AC-BC47-71CA54BBCBE1Q35564256-A10231F8-501F-4C3E-BB57-81FAA1AE1674Q35748345-1C41FDFC-732E-474E-BAAC-8E3789965412Q36078803-94C8F391-013D-4E4D-B949-01A059E6BC46Q36166654-4009D12D-6DDF-4637-AF50-20B4420C3BC3Q36211439-B11E1717-42BC-4081-A0A9-D52966E1647BQ36253100-FFAC8881-FF66-46BD-8551-B57CBD20B458Q36279695-D38662F2-41A0-40C7-8035-BE9A2510E0E2Q36293649-FA09A91D-F9BF-4B89-A858-1E6D2085732CQ36905790-CCD46047-B02E-469D-9356-9FB1DB987497Q37078997-BDC39769-C4DE-4C09-99A5-2D5A20A63114Q37212333-BDB5A23E-8552-4CEB-9331-2A8F7DC4BDFCQ37424923-813DE099-7BC8-42BA-90F6-9435D77B2536Q37686556-7DDA7541-7444-4AEE-9922-B71A1CCE71B4Q37894864-448C6101-685A-453F-A6F2-ED8B2A4E77BCQ37900307-3F7CAB55-0404-44E2-8402-6552B2869FFBQ37950344-FD287BB4-4431-429B-A86A-214F46328840Q37988796-53A34F62-2A3B-40C9-BAFE-35BB569DB60BQ38064967-2F6FF1BE-8C43-4B60-A5F0-71D1A8B4353F
P2860
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
A novel neurotrophic property ...... differentiation in PC12 cells.
@en
type
label
A novel neurotrophic property ...... differentiation in PC12 cells.
@en
prefLabel
A novel neurotrophic property ...... differentiation in PC12 cells.
@en
P2093
P356
P1476
A novel neurotrophic property ...... differentiation in PC12 cells.
@en
P2093
Debomoy K Lahiri
Demao Chen
Karen T Y Shaw
Nigel H Greig
TracyAnn Perry
P304
P356
10.1124/JPET.300.3.958
P407
P577
2002-03-01T00:00:00Z